Oprozomib in patients with newly diagnosed multiple myeloma
Open Access
- 16 August 2019
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 9 (9) , 1-4
Abstract
No abstract availableKeywords
Funding Information
- Amgen Foundation
This publication has 11 references indexed in Scilit:
- Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myelomaLeukemia Research, 2019
- A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)Clinical Lymphoma Myeloma and Leukemia, 2017
- Myeloma: management of the newly diagnosed high-risk patientHematology-American Society Hematology Education Program, 2016
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myelomaBlood, 2015
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaJAMA Oncology, 2015
- Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label StudyBlood, 2014
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studyBlood, 2014
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaBlood, 2012
- Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studiesLeukemia & Lymphoma, 2010
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)Journal of Medicinal Chemistry, 2009